<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02149901</url>
  </required_header>
  <id_info>
    <org_study_id>140547</org_study_id>
    <secondary_id>P01HL056693</secondary_id>
    <secondary_id>UL1TR000445</secondary_id>
    <nct_id>NCT02149901</nct_id>
  </id_info>
  <brief_title>Water and Sudafed in Autonomic Failure</brief_title>
  <official_title>Effect of Drinking Water on the Pressor Response to Pseudoephedrine in Patients With Autonomic Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Heart, Lung, and Blood Institute (NHLBI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Advancing Translational Science (NCATS)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The specific aim of this study is to determine whether water ingestion potentiates the&#xD;
      pressor response to pseudoephedrine in patients with primary disorders of autonomic failure.&#xD;
      The study design will enable us to also evaluate the pressor response to water alone and to&#xD;
      pseudoephedrine alone. In a secondary analysis, we will compare the results in patients with&#xD;
      two autonomic disorders, pure autonomic failure (PAF) and multiple system atrophy (MSA). We&#xD;
      hypothesize that drinking water following a dose of pseudoephedrine will lead to a greater&#xD;
      increase in blood pressure than pseudoephedrine alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximal pressor response to water is reached when other pressor agents are only beginning&#xD;
      to act. In addition to the therapeutic value of water ingestion alone, the blood&#xD;
      pressure-raising effects of agents that increase sympathetic nervous system tone, such as&#xD;
      phenylpropanolamine, are potentiated by water drinking. These drug interaction effects can be&#xD;
      exploited in the treatment of orthostatic hypotension with the combination of water and a&#xD;
      sympathomimetic potentially able to increase blood pressure to a greater extent and for a&#xD;
      longer period of time than either water or the medication alone. However, the interaction can&#xD;
      also lead to potentially dangerous blood pressure surges.&#xD;
&#xD;
      This protocol requires an initial screening history and physical of study participants,&#xD;
      including safety labs and EKGs, and evaluation of their autonomic nervous system status&#xD;
      following the consent process. If the patient meets study criteria and is willing to undergo&#xD;
      study testing, the 4-way crossover protocol will follow.&#xD;
&#xD;
      Study Testing days 1 and 2 Arm 1: Pseudoephedrine 30 mg PO + 50 ml water Arm 2:&#xD;
      Pseudoephedrine 30 mg PO + 480 ml water&#xD;
&#xD;
        -  Testing will be performed at the same time of day for all studies, at least 2 hours&#xD;
           after a meal to avoid any confounding effects from postprandial hypotension.&#xD;
&#xD;
        -  A saline lock will be inserted for blood sampling at least 30 minutes before baseline&#xD;
           data collection.&#xD;
&#xD;
        -  Participants will be asked to empty their bladders before beginning the test to avoid&#xD;
           any effect of a full urinary bladder on peripheral sympathetic activity.&#xD;
&#xD;
        -  Participants will be seated comfortably in a chair. They will be asked to remain in the&#xD;
           seated position for the duration of the study.&#xD;
&#xD;
        -  The Dinamap electrocardiographic and blood pressure (brachial cuff) recorder will be&#xD;
           attached to the patient and set up for measurements every 5 minutes throughout the study&#xD;
           with digital download into the ADC (Autonomic Dysfunction Center) BP database.&#xD;
&#xD;
        -  Participants will also be instrumented with EKG, finger cuff and sensor for continuous&#xD;
           monitoring of blood pressure, heart rate, respiration, SpO2, stroke volume, systemic&#xD;
           vascular resistance, and cardiac output, using a Nexfin system and Ivy Biomedical&#xD;
           Vital-Guard monitor.&#xD;
&#xD;
        -  After a 30 minute baseline monitoring period (time -30 min to 0 min), 4 ½ teaspoons of&#xD;
           blood will be collected for osmolality measurement and assays of hormones that regulate&#xD;
           blood pressure.&#xD;
&#xD;
        -  The subject will then be given 30 mg of pseudoephedrine PO (time 0 min). Monitoring will&#xD;
           be continued for 45 minutes.&#xD;
&#xD;
        -  At 45 minutes, the participant will be asked to drink 50 ml (Arm 1) or 480 ml (Arm 2) of&#xD;
           water.&#xD;
&#xD;
        -  Additional blood samples (4 ½ teaspoons) for osmolality and BP-regulating hormones will&#xD;
           be collected 30 and 60 minutes after water (+75 and +105 minutes of study).&#xD;
&#xD;
        -  Monitoring will be continued until + 135 min.&#xD;
&#xD;
        -  At 135 minutes, the study will end for the day. The timing of pseudoephedrine&#xD;
           administration relative to water ingestion and the duration of the monitoring period are&#xD;
           based on previous results3 and pharmacokinetic data7 reporting a Tmax for&#xD;
           pseudoephedrine between 1 and 2 hours. Testing on study day 2 will be identical with the&#xD;
           participant consuming the alternate water volume.&#xD;
&#xD;
      Study Testing days 3 and 4 are optional Arm 3: Placebo PO + 50 ml water Arm 4: Placebo PO +&#xD;
      480 ml water Testing will be performed according to the same schedule as for Arms 1 and 2.&#xD;
      Instrumentation will be limited to the Dinamap electrocardiographic and blood pressure&#xD;
      (brachial cuff) recorder set up for measurements every 5 minutes throughout the study for&#xD;
      Arms 3 and 4.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    funding terminated&#xD;
  </why_stopped>
  <start_date>October 2014</start_date>
  <completion_date type="Actual">December 2020</completion_date>
  <primary_completion_date type="Actual">December 2020</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary outcome measure in each Aim will be the peak increase in systolic blood pressure after pseudoephedrine or placebo relative to baseline (delta SBP).</measure>
    <time_frame>between 60 and 120 minutes after pseudoephedrine or placebo</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in diastolic blood pressure relative to baseline</measure>
    <time_frame>between 60 and 120 minutes after pseudoephedrine or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in heart rate relative to baseline</measure>
    <time_frame>between 60 and 120 minutes after pseudoephedrine or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute systolic blood pressure after treatment</measure>
    <time_frame>between 60 and 120 minutes after pseudoephedrine and placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute diastolic blood pressure after treatment</measure>
    <time_frame>between 60 and 120 minutes after pseudoephedrine or placebo</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>area under the curve for systolic blood pressure from baseline to 135 minutes post-treatment</measure>
    <time_frame>from baseline to 135 minutes after pseudoephedrine or placebo</time_frame>
    <description>Area under the curve can better measure an extension of the duration of response.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak plasma norepinephrine concentration after treatment</measure>
    <time_frame>between baseline and 135 minutes after pseudoephedrine or placebo</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Shy-Drager Syndrome</condition>
  <condition>Multiple System Atrophy</condition>
  <arm_group>
    <arm_group_label>Pseudoephedrine + 480 ml water</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pseudoephedrine 30 mg PO 45 minutes before water 480 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Pseudoephedrine + 50 ml water</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Pseudoephedrine 30 mg PO 45 minutes before water 50 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + 480 ml water (optional)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Placebo PO 45 minutes before water 480 ml</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo + 50 ml water (optional)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo PO 45 minutes before water 50 ml</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudoephedrine + 480 ml water</intervention_name>
    <description>30 mg pseudoephedrine to be given with a pressor dose (480 ml) of drinking water</description>
    <arm_group_label>Pseudoephedrine + 480 ml water</arm_group_label>
    <other_name>Sudafed</other_name>
    <other_name>drinking water</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudoephedrine + 50 ml water</intervention_name>
    <description>Pseudoephedrine given with a non-pressor (50 ml) dose of drinking water</description>
    <arm_group_label>Pseudoephedrine + 50 ml water</arm_group_label>
    <other_name>Sudafed</other_name>
    <other_name>drinking water</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo + 480 ml water (optional)</intervention_name>
    <description>placebo PO with a pressor (480 ml) dose of drinking water</description>
    <arm_group_label>Placebo + 480 ml water (optional)</arm_group_label>
    <other_name>drinking water</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo + 50 ml water (optional)</intervention_name>
    <description>placebo PO with a non-pressor (50 ml) dose of drinking water</description>
    <arm_group_label>Placebo + 50 ml water (optional)</arm_group_label>
    <other_name>drinking water</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-80 years, with&#xD;
&#xD;
          -  Neurogenic orthostatic hypotension, ≥30 mmHg drop in SBP within 5 minutes of standing,&#xD;
&#xD;
          -  Associated with impaired autonomic reflexes, as determined by absence of blood&#xD;
             pressure overshoot during phase IV of the valsalva maneuver,&#xD;
&#xD;
          -  Absence of other identifiable causes of autonomic neuropathy, and&#xD;
&#xD;
          -  Able and willing to provide informed consent&#xD;
&#xD;
        Exclusion Criteria&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Current smoking habit&#xD;
&#xD;
          -  Systemic illnesses known to produce autonomic neuropathy, including but not limited to&#xD;
             diabetes mellitus, amyloidosis, monoclonal gammopathy of unknown significance, and&#xD;
             autoimmune neuropathies.&#xD;
&#xD;
          -  Known intolerance to pseudoephedrine&#xD;
&#xD;
          -  Pre-existing sustained severe hypertension (BP &gt; 180/110 mmHg in the sitting position)&#xD;
&#xD;
          -  Clinically unstable coronary artery disease or major cardiovascular or neurological&#xD;
             event in the past 6 months.&#xD;
&#xD;
          -  Any other significant systemic, hepatic, cardiac or renal illness&#xD;
&#xD;
          -  Use of MAO-I (i.e. selegiline; rasagiline - Azilect, linezolid and others) within 14&#xD;
             days&#xD;
&#xD;
          -  Known closed-angle glaucoma&#xD;
&#xD;
          -  Clinically meaningful arrhythmias&#xD;
&#xD;
          -  Other factors which in the investigator's opinion would prevent the participant from&#xD;
             completing the protocol, including poor compliance during previous studies or an&#xD;
             unpredictable schedule&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emily M Garland, PhD, MSCI</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Jordan J, Shannon JR, Grogan E, Biaggioni I, Robertson D. A potent pressor response elicited by drinking water. Lancet. 1999 Feb 27;353(9154):723.</citation>
    <PMID>10073520</PMID>
  </reference>
  <reference>
    <citation>Jordan J, Shannon JR, Black BK, Ali Y, Farley M, Costa F, Diedrich A, Robertson RM, Biaggioni I, Robertson D. The pressor response to water drinking in humans : a sympathetic reflex? Circulation. 2000 Feb 8;101(5):504-9.</citation>
    <PMID>10662747</PMID>
  </reference>
  <reference>
    <citation>Jordan J, Shannon JR, Diedrich A, Black B, Robertson D, Biaggioni I. Water potentiates the pressor effect of ephedra alkaloids. Circulation. 2004 Apr 20;109(15):1823-5. Epub 2004 Apr 5.</citation>
    <PMID>15066944</PMID>
  </reference>
  <reference>
    <citation>Kobayashi S, Endou M, Sakuraya F, Matsuda N, Zhang XH, Azuma M, Echigo N, Kemmotsu O, Hattori Y, Gando S. The sympathomimetic actions of l-ephedrine and d-pseudoephedrine: direct receptor activation or norepinephrine release? Anesth Analg. 2003 Nov;97(5):1239-1245. doi: 10.1213/01.ANE.0000092917.96558.3C.</citation>
    <PMID>14570629</PMID>
  </reference>
  <reference>
    <citation>Rothman RB, Vu N, Partilla JS, Roth BL, Hufeisen SJ, Compton-Toth BA, Birkes J, Young R, Glennon RA. In vitro characterization of ephedrine-related stereoisomers at biogenic amine transporters and the receptorome reveals selective actions as norepinephrine transporter substrates. J Pharmacol Exp Ther. 2003 Oct;307(1):138-45. Epub 2003 Sep 3.</citation>
    <PMID>12954796</PMID>
  </reference>
  <reference>
    <citation>Lu CC, Diedrich A, Tung CS, Paranjape SY, Harris PA, Byrne DW, Jordan J, Robertson D. Water ingestion as prophylaxis against syncope. Circulation. 2003 Nov 25;108(21):2660-5. Epub 2003 Nov 17. Erratum in: Circulation. 2005 Apr 5;111(13):1717.</citation>
    <PMID>14623807</PMID>
  </reference>
  <reference>
    <citation>Kanfer I, Dowse R, Vuma V. Pharmacokinetics of oral decongestants. Pharmacotherapy. 1993 Nov-Dec;13(6 Pt 2):116S-128S; discussion 143S-146S. Review.</citation>
    <PMID>7507589</PMID>
  </reference>
  <reference>
    <citation>Dupont WD, Plummer WD Jr. Power and sample size calculations. A review and computer program. Control Clin Trials. 1990 Apr;11(2):116-28.</citation>
    <PMID>2161310</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 26, 2014</study_first_submitted>
  <study_first_submitted_qc>May 26, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 29, 2014</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University</investigator_affiliation>
    <investigator_full_name>Emily M. Garland</investigator_full_name>
    <investigator_title>Research Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Pure Autonomic Failure</keyword>
  <keyword>Multiple System Atrophy</keyword>
  <keyword>Pseudoephedrine</keyword>
  <keyword>Water</keyword>
  <keyword>Osmopressor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Pure Autonomic Failure</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

